Shire/Baxalta Merger

This essay was featured in the BloodStream Pod.

   On June 3, 2016, Shire announced its combination with Baxalta in a $32 million merger that will notably expand its global reach. The combination positions Shire as the, “global leader in rare diseases.”  In addition to the significant anticipated revenue, the announcement also signals substantial development and innovation of next generation treatment therapies.  Read more about the combination here.